Cartalax vs Palmitoyl Tripeptide-1

Tetrapeptide bioregulator from cartilage tissue; stimulates chondrocyte proliferation and extracellular matrix synthesis; normalizes gene expression in cartilage cells

Cartalax is a Khavinson-class short bioregulator peptide investigated for connective tissue and cartilage maintenance. Like other ultrashort peptides in this research category, cartalax is proposed to reach musculoskeletal target cells via amino acid transporter mechanisms and influence gene expression pathways associated with cellular aging. Published preclinical studies of structurally related Khavinson peptides show regulation of aging-associated genes and epigenetic markers in mesenchymal stem cell models. Human clinical evidence specific to cartalax is limited; existing research is predominantly preclinical and based on related peptides within the same class. Cartalax benefits investigated in preclinical research include support for chondrocyte proliferation, extracellular matrix synthesis, and cartilage tissue homeostasis — areas relevant to age-related joint degeneration, osteoarthritis research, and connective tissue maintenance. As a bioregulator peptide, cartalax is proposed to work by modulating gene expression in cartilage-specific cells rather than providing direct structural repair, distinguishing it mechanistically from direct injections of growth factors or PRP. Research interest also extends to combined bioregulator protocols pairing cartalax with other Khavinson-class peptides targeting musculoskeletal and connective tissue health, including protocols used alongside cortagen for vascular-connective tissue support. Cartalax dosage: No human clinical trial has established a reference dose for cartalax. Preclinical research protocols in the Khavinson bioregulator literature have examined peptide bioregulators at doses in the microgram-to-low-milligram range via subcutaneous injection, typically administered in defined cycles. Oral bioregulator formulations of related Khavinson peptides have also been studied. Cartalax is a research compound with no approved human dosing guidelines.

Palmitoylated GHK fragment; stimulates collagen I, III, and IV synthesis via TGF-β pathway; increases fibronectin and hyaluronic acid production

Palmitoyl Tripeptide-1 (Pal-GHK) is a fatty-acid-conjugated form of the copper-binding tripeptide GHK (glycine-histidine-lysine), widely used in cosmetic formulations targeting skin firmness and matrix support. GHK is a naturally occurring human plasma peptide that modulates collagen and elastin synthesis, matrix remodeling enzyme activity, and antioxidant gene expression. Conjugating GHK to palmitic acid (a fatty acid) significantly improves transdermal penetration, allowing the peptide to reach the fibroblast-rich dermis from topical application — addressing the primary limitation of unmodified GHK, which does not readily cross the stratum corneum barrier. Pal-GHK vs GHK-Cu: Palmitoyl Tripeptide-1 (Pal-GHK) and GHK-Cu (copper peptide) derive from the same GHK tripeptide backbone but are formulated differently. GHK-Cu complexes GHK with copper(II) ions to leverage the copper-mediated wound healing and antioxidant mechanisms of the peptide. Pal-GHK conjugates GHK with palmitic acid for improved dermal penetration without the copper component. Both are used in anti-aging cosmetic formulations; GHK-Cu is used in injectable/serum contexts where copper activity is desired, while Pal-GHK appears predominantly in cosmetic skincare products where lipid-conjugated delivery is the priority. Matrixyl Synthe'6 context: Palmitoyl Tripeptide-1 is a primary active in Sederma's Matrixyl Synthe'6 formulation, which combines six components proposed to support six key structural proteins of the skin matrix: collagen I, III, and IV, fibronectin, laminin-5, and hyaluronic acid. The combination positions Pal-GHK as the collagen-stimulating component within a broader matrix-targeting blend, distinguishing Matrixyl Synthe'6 from the original Matrixyl (palmitoyl pentapeptide-4) and Matrixyl 3000 formulations. Products containing Matrixyl Synthe'6 list palmitoyl tripeptide-1 as an INCI ingredient alongside palmitoyl tetrapeptide-38 and other actives. Research and formulation: In vitro studies on palmitoyl tripeptide-1 show stimulation of collagen I and III synthesis in human fibroblast cultures. Clinical evidence is primarily from manufacturer-sponsored cosmetic studies showing improvements in skin firmness metrics. Palmitoyl Tripeptide-1 is included in the Cosmetics Europe Colipa ingredient database; it is not classified as a drug in any major jurisdiction. Concentrations in cosmetic formulations typically range from 2–5% of the palmitoyl tripeptide-1 ingredient solution (peptide content within the solution is lower, per the Sederma concentrate formulation). It is available exclusively in topical cosmetic form — there is no injectable or clinical application for this compound.